Equities

PRISM BioLab Co Ltd

206A:TYO

PRISM BioLab Co Ltd

Actions
  • Price (JPY)477.00
  • Today's Change12.00 / 2.58%
  • Shares traded253.30k
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PRISM BioLab Co Ltd is a Japan-based company mainly engaged in the drug discovery business. The Company operates through Japan drug discovery business segment. The Company builds a new drug discovery platform and develops new drugs. The Company conducts research and development of pharmaceuticals using their owned drug discovery platform technology PepMetics technology. There are two business models. The in-house development business is engaged in the select of drug discovery targets and creates programs in-house. The joint development business creates programs using their owned technology to target drug discovery targets for pharmaceutical companies.

  • Revenue in JPY (TTM)--
  • Net income in JPY--
  • Incorporated2012
  • Employees22.00
  • Location
    PRISM BioLab Co LtdShonan I Park, 2-26-1, Muraoka-HigashiFUJISAWA-SHI 251-8555JapanJPN
  • Phone+81 466538383
  • Fax+81 466549393
  • Websitehttps://prismbiolab.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Noile-Immune Biotech Inc308.06m-979.88m8.70bn28.00--1.74--28.25-22.63-22.637.11115.620.05490.06256.3511,002,180.00-17.47---17.90--99.80---318.08--66.40--0.00---49.37---192.28------
Linical Co Ltd12.15bn252.44m9.85bn662.0035.611.1012.510.810311.1811.18538.03362.320.6633--3.4518,356,870.001.384.012.376.3329.2630.992.085.48----0.251850.81-1.671.70-66.32-9.86-10.184.56
OncoTherapy Science, Inc.562.70m-1.19bn10.87bn54.00--14.31--19.31-5.39-5.392.552.800.44315.1815.9410,420,280.00-93.70-55.67-129.70-63.82-30.63-1.49-211.47-247.472.67-255.180.1146---46.2416.81-15.15---48.33--
3-D Matrix Ltd5.25bn-1.05bn11.50bn106.00--10.20--2.19-12.89-12.8966.8811.660.85590.5515.4049,502,420.00-17.15-42.10-21.31-55.6068.3853.95-20.04-96.032.51--0.7979--98.3069.4189.55---30.34--
Tsubota Laboratory Inc674.29m-691.35m11.69bn7.00--9.80--17.34-27.06-27.0626.3846.620.29741.83465.3596,327,430.00-30.50---42.97--7.89---102.53--2.20-434.240.085---29.45---811.14------
Medinet Co Ltd759.11m-1.34bn11.90bn98.00--2.22--15.68-5.53-5.533.1020.310.134711.643.737,745,980.00-23.85-21.05-24.99-22.4717.7828.75-177.09-135.4018.90--0.00--4.40-7.90-14.66---17.67--
Nano Mrna Co Ltd76.60m-650.31m13.77bn18.00--4.21--179.79-9.24-9.241.0946.270.014524.081.454,255,556.00-12.33-24.16-13.57-25.1778.3084.69-848.97-600.709.24--0.2540---32.98-22.8840.50------
PRISM BioLab Co Ltd-100.00bn-100.00bn16.72bn22.00--7.01----------66.29----------------------------0.00---79.63---822.18------
AnGes Inc449.34m-6.11bn19.14bn145.00--0.7267--42.59-29.92-29.922.22107.330.01390.19314.023,098,862.00-18.95-28.50-22.32-33.1438.7939.42-1,359.35-6,726.821.19--0.013--128.13-24.1749.45--12.11--
Healios KK522.00m-5.39bn21.72bn64.00--6.69--41.61-68.16-68.166.5636.000.0321--1.618,156,250.00-33.11-23.55-49.17-28.5285.06---1,030.65-6,580.16---1.490.7469--34.44--26.04---22.00--
Data as of Sep 20 2024. Currency figures normalised to PRISM BioLab Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

0.15%Per cent of shares held by top holders
HolderShares% Held
Simplex Asset Management Co., Ltd.as of 05 Sep 202453.70k0.15%
Data from 12 Sep 2024 - 12 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.